Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Embryonic FAP+ lymphoid tissue organizer cells generate the reticular network of adult lymph nodes.

Denton AE, Carr EJ, Magiera LP, Watts AJB, Fearon DT.

J Exp Med. 2019 Jul 19. pii: jem.20181705. doi: 10.1084/jem.20181705. [Epub ahead of print]

PMID:
31324739
2.

Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology.

Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, Roulois D, Turner J, Sylvestre M, Asam S, Glaysher B, Bowman SJ, Fearon DT, Filer A, Tarte K, Luther SA, Fisher BA, Buckley CD, Coles MC, Barone F.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13490-13497. doi: 10.1073/pnas.1905301116. Epub 2019 Jun 18.

3.

Distinct fibroblast subsets drive inflammation and damage in arthritis.

Croft AP, Campos J, Jansen K, Turner JD, Marshall J, Attar M, Savary L, Wehmeyer C, Naylor AJ, Kemble S, Begum J, Dürholz K, Perlman H, Barone F, McGettrick HM, Fearon DT, Wei K, Raychaudhuri S, Korsunsky I, Brenner MB, Coles M, Sansom SN, Filer A, Buckley CD.

Nature. 2019 Jun;570(7760):246-251. doi: 10.1038/s41586-019-1263-7. Epub 2019 May 29.

PMID:
31142839
4.

Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.

Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, Upadhyay P, Uyeminami DL, Pommier A, Küttner V, Bružas E, Maiorino L, Bautista C, Carmona EM, Gimotty PA, Fearon DT, Chang K, Lyons SK, Pinkerton KE, Trotman LC, Goldberg MS, Yeh JT, Egeblad M.

Science. 2018 Sep 28;361(6409). pii: eaao4227. doi: 10.1126/science.aao4227.

PMID:
30262472
5.

Stromal Cells in the Tumor Microenvironment.

Denton AE, Roberts EW, Fearon DT.

Adv Exp Med Biol. 2018;1060:99-114. doi: 10.1007/978-3-319-78127-3_6. Review.

PMID:
30155624
6.

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases.

Pommier A, Anaparthy N, Memos N, Kelley ZL, Gouronnec A, Yan R, Auffray C, Albrengues J, Egeblad M, Iacobuzio-Donahue CA, Lyons SK, Fearon DT.

Science. 2018 Jun 15;360(6394). pii: eaao4908. doi: 10.1126/science.aao4908. Epub 2018 May 17.

7.

Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, Wu D, Loughran RM, Emerling BM, Zhang G, Fearon DT, Cantley LC.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E743-E752. doi: 10.1073/pnas.1714703115. Epub 2018 Jan 8. Erratum in: Proc Natl Acad Sci U S A. 2018 Feb 20;:.

8.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, Wells DK, Cary CIO, Grbovic-Huezo O, Attiyeh M, Medina B, Zhang J, Loo J, Saglimbeni J, Abu-Akeel M, Zappasodi R, Riaz N, Smoragiewicz M, Kelley ZL, Basturk O; Australian Pancreatic Cancer Genome Initiative; Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research Institute; University of Melbourne, Centre for Cancer Research; University of Queensland, Institute for Molecular Bioscience; Bankstown Hospital; Liverpool Hospital; Royal Prince Alfred Hospital, Chris O’Brien Lifehouse; Westmead Hospital; Fremantle Hospital; St John of God Healthcare; Royal Adelaide Hospital; Flinders Medical Centre; Envoi Pathology; Princess Alexandria Hospital; Austin Hospital; Johns Hopkins Medical Institutes; ARC-Net Centre for Applied Research on Cancer, Gönen M, Levine AJ, Allen PJ, Fearon DT, Merad M, Gnjatic S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD.

Nature. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8.

9.

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring.

Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11.

10.

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes.

Connell CM, Raby S, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T.

Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181. No abstract available.

11.

Connecting the Metabolic and Immune Responses to Cancer.

Flint TR, Fearon DT, Janowitz T.

Trends Mol Med. 2017 May;23(5):451-464. doi: 10.1016/j.molmed.2017.03.001. Epub 2017 Apr 7. Review.

PMID:
28396056
12.

Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities.

Fearon DT.

Cold Spring Harb Symp Quant Biol. 2016;81:219-226. doi: 10.1101/sqb.2016.81.030783. Epub 2017 Apr 7.

PMID:
28389597
13.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA.

J Exp Med. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23.

14.

Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.

Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT.

Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010.

15.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

16.

T cell exclusion, immune privilege, and the tumor microenvironment.

Joyce JA, Fearon DT.

Science. 2015 Apr 3;348(6230):74-80. doi: 10.1126/science.aaa6204. Review.

PMID:
25838376
17.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

18.

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.

Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.

19.

Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.

Dos Santos LI, Galvão-Filho B, de Faria PC, Junqueira C, Dutra MS, Teixeira SM, Rodrigues MM, Ritter G, Bannard O, Fearon DT, Antonelli LR, Gazzinelli RT.

Cancer Immunol Immunother. 2015 Mar;64(3):311-23. doi: 10.1007/s00262-014-1634-8. Epub 2014 Nov 18.

PMID:
25403749
20.

Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells.

Denton AE, Roberts EW, Linterman MA, Fearon DT.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12139-44. doi: 10.1073/pnas.1412910111. Epub 2014 Aug 4.

21.

The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.

Fearon DT.

Cancer Immunol Res. 2014 Mar;2(3):187-93. doi: 10.1158/2326-6066.CIR-14-0002.

22.

Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Arnold JN, Magiera L, Kraman M, Fearon DT.

Cancer Immunol Res. 2014 Feb;2(2):121-6. doi: 10.1158/2326-6066.CIR-13-0150. Epub 2013 Nov 18.

23.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

24.

Transcriptional regulation of effector and memory CD8+ T cell fates.

Thaventhiran JE, Fearon DT, Gattinoni L.

Curr Opin Immunol. 2013 Jun;25(3):321-8. doi: 10.1016/j.coi.2013.05.010. Epub 2013 Jun 6. Review.

25.

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia.

Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, Brindle KM, Teichmann SA, Tuveson DA, Fearon DT.

J Exp Med. 2013 Jun 3;210(6):1137-51. doi: 10.1084/jem.20122344. Epub 2013 May 27.

26.

Control of HIV infection: escape from the shadow of Blimp-1.

Thaventhiran JE, Fearon DT.

Eur J Immunol. 2013 Feb;43(2):323-6. doi: 10.1002/eji.201243263.

27.

Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell.

Thaventhiran JE, Hoffmann A, Magiera L, de la Roche M, Lingel H, Brunner-Weinzierl M, Fearon DT.

Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):E2223-9. doi: 10.1073/pnas.1209115109. Epub 2012 Jun 27.

28.

siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFNA2 activation and IL-8 secretion.

Charlaftis N, Fearon DT, Schoenemeyer A, Morley PJ.

Biotechnol Appl Biochem. 2012 Jan-Feb;59(1):6-14. doi: 10.1002/bab.66. Epub 2012 Jan 23.

PMID:
22332739
29.

Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection.

Mackay LK, Wakim L, van Vliet CJ, Jones CM, Mueller SN, Bannard O, Fearon DT, Heath WR, Carbone FR.

J Immunol. 2012 Mar 1;188(5):2173-8. doi: 10.4049/jimmunol.1102719. Epub 2012 Jan 23.

30.

T-bet-mediated differentiation of the activated CD8+ T cell.

Yeo CJ, Fearon DT.

Eur J Immunol. 2011 Jan;41(1):60-6. doi: 10.1002/eji.201040873. Epub 2010 Dec 9.

31.

Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection.

Bannard O, Kraman M, Fearon DT.

J Immunol. 2010 Dec 15;185(12):7141-5. doi: 10.4049/jimmunol.1002537. Epub 2010 Nov 10.

32.

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT.

Science. 2010 Nov 5;330(6005):827-30. doi: 10.1126/science.1195300.

33.
34.

The precursors of memory: models and controversies.

Ahmed R, Bevan MJ, Reiner SL, Fearon DT.

Nat Rev Immunol. 2009 Sep;9(9):662-8. doi: 10.1038/nri2619. Epub 2009 Aug 14. Review.

PMID:
19680250
35.

Secondary replicative function of CD8+ T cells that had developed an effector phenotype.

Bannard O, Kraman M, Fearon DT.

Science. 2009 Jan 23;323(5913):505-9. doi: 10.1126/science.1166831.

36.

Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist.

Fearon WF, Fearon DT.

Circulation. 2008 May 20;117(20):2577-9. doi: 10.1161/CIRCULATIONAHA.108.772491. Review. No abstract available.

PMID:
18490534
37.

The expansion and maintenance of antigen-selected CD8(+) T cell clones.

Fearon DT.

Adv Immunol. 2007;96:103-39. Review.

PMID:
17981205
38.

Loss of T cell receptor-induced Bmi-1 in the KLRG1(+) senescent CD8(+) T lymphocyte.

Heffner M, Fearon DT.

Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13414-9. Epub 2007 Aug 8.

39.

CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation.

Carr JM, Carrasco MJ, Thaventhiran JE, Bambrough PJ, Kraman M, Edwards AD, Al-Shamkhani A, Fearon DT.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19454-9. Epub 2006 Dec 11.

40.

The rationale for the IL-2-independent generation of the self-renewing central memory CD8+ T cells.

Fearon DT, Carr JM, Telaranta A, Carrasco MJ, Thaventhiran JE.

Immunol Rev. 2006 Jun;211:104-18. Review.

PMID:
16824121
41.

Identifying genes important for spermatogonial stem cell self-renewal and survival.

Oatley JM, Avarbock MR, Telaranta AI, Fearon DT, Brinster RL.

Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9524-9. Epub 2006 Jun 1.

42.

The proto-oncogene BCL-6 is expressed in olfactory sensory neurons.

Otaki JM, Fearon DT, Yamamoto H.

Neurosci Res. 2005 Oct;53(2):189-200.

PMID:
16055217
43.

BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes.

Manders PM, Hunter PJ, Telaranta AI, Carr JM, Marshall JL, Carrasco M, Murakami Y, Palmowski MJ, Cerundolo V, Kaech SM, Ahmed R, Fearon DT.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7418-25. Epub 2005 Apr 15.

44.

Bcl-6 uncouples B lymphocyte proliferation from differentiation.

Fearon DT, Manders PM, Wagner SD.

Adv Exp Med Biol. 2002;512:21-8. Review. No abstract available.

PMID:
12405183
45.

Arrested differentiation, the self-renewing memory lymphocyte, and vaccination.

Fearon DT, Manders P, Wagner SD.

Science. 2001 Jul 13;293(5528):248-50. Review.

PMID:
11452114
46.

IgM and stromal cell-associated heparan sulfate/heparin as complement-independent ligands for CD19.

de Fougerolles AR, Batista F, Johnsson E, Fearon DT.

Eur J Immunol. 2001 Jul;31(7):2189-99.

PMID:
11449373
47.

Innate immunity--beginning to fulfill its promise?

Fearon DT.

Nat Immunol. 2000 Aug;1(2):102-3. Review. No abstract available.

PMID:
11248799
48.
49.
50.

Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex.

Fearon DT, Carroll MC.

Annu Rev Immunol. 2000;18:393-422. Review.

PMID:
10837064

Supplemental Content

Loading ...
Support Center